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Abstract
Although expression of estrogen receptor (ER), progesterone receptor (PR), and cell proliferation 
marker Ki67 serve as predictive and prognostic factors in breast cancers, little is known about their 
roles in normal breast tissue. Here in a nested case–control study within the Nurses’ Health 
Studies (90 cases, 297 controls), we evaluated their expression levels in normal breast epithelium 
in relation to subsequent breast cancer risk among women with benign breast disease. Tissue 
microarrays were constructed using cores obtained from benign biopsies containing normal 
terminal duct lobular units and immunohistochemical stained for these markers. We found PR and 
Ki67 expression was non-significantly but positively associated with subsequent breast cancer 
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risk, whereas ER expression was non-significantly inversely associated. After stratifying by lesion 
subtype, Ki67 was significantly associated with higher risk among women with proliferative 
lesions with atypical hyperplasia. However, given the small sample size, further studies are 
required to confirm these results.
Development of breast neoplasia involves hormones such as estrogens and progesterone that 
regulate cell proliferation and apoptosis. The tissue-specific responsiveness to these 
hormones is partially regulated by the tissue expression of receptors that bind them.1 Ki67 is 
a cell proliferation marker, as it is present only during active phases of the cell cycle.2 
Although expression of estrogen receptor α (ER), progesterone receptor (PR), and Ki67 
serve as predictive and prognostic factors in breast cancer, little is known about their roles in 
normal breast tissue. In a nested case–control study within the Nurses’ Health Study (NHS) 
and NHSII cohorts, we examined the associations of ER, PR, and Ki67 expression levels in 
normal breast epithelium with subsequent breast cancer risk among women with a previous 
diagnosis of benign breast disease (BBD).
Briefly, controls were matched to cases on age, calendar year of BBD, and time since 
biopsy. Archived formalin-fixed paraffin-embedded biopsy blocks were collected from 
pathology departments for cases and controls. Tissue microarrays (TMAs) were constructed 
by obtaining 0.6-mm cores of benign lesions and adjacent normal terminal duct lobular units 
(TDLUs).3 A 5-μm section from each TMA block was immunohistochemically stained with 
each antibody (ERα: clone SP1, Neomarkers, CA, USA; PR: clone PgR 636, Dako 
Corporation, CA, USA; Ki67: clone SP6, Vector Laboratories, CA, USA). Immunostaining 
results were interpreted using an automated computational image analysis system (Definiens 
Tissue Studio software, Munich, Germany); scoring algorithms are shown in Supplementary 
Figures 1–3. The automated scores were moderately correlated with manually scored data on 
select TMAs that we scored using both methods (Spearman r = 0.40–0.48). For each woman, 
we estimated the mean percentage of stain-positive cells across the cores, by weighting each 
core by its total cell count. Women were excluded if they had evidence of carcinoma at 
biopsy or within 6 months of their biopsy, there was not enough tissue on the block for TMA 
construction, had low cellularity (<100 cells), or had no evaluable marker staining. Details of 
the methods are described in Supplementary Appendix.
Among 90 breast cancer cases and 297 controls who were included in the analysis, the mean 
age at BBD biopsy was 45.4 years. The average time between the BBD biopsy and the 
breast cancer diagnosis was 9.0 years (range: 6 months to 31.3 years). Distributions of 
population characteristics and marker staining are presented in Supplementary Tables 1 and 
2. The median percentages of ER-positive, PR-positive, and Ki67-positive cells in normal 
TDLUs were 10%, 7%, and 4%, respectively, which were comparable to levels that have 
been previously reported.4–6 Although the expression levels varied slightly by its adjacent 
lesion type, the differences were not statistically significant (Supplementary Table 3). The 
intraclass correlation coefficients across cores ranged from 0.26 for Ki67 to 0.45 for ER, 
suggesting some within-person variability across the cores due to true heterogeneity in 
tissues7 and possibly methodological artifacts. The Spearman correlation for markers in 
normal TDLUs was modest between ER and PR (r = 0.35) but minimal between other 
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markers (Supplementary Table 4). When comparing expression levels of normal TDLUs 
with subsequent breast tumor tissues among cases, the levels were higher in tumor tissue 
(Supplementary Table 5) as expected5,6 and the Spearman correlations were modest for PR 
(r = 0.21) and Ki67 (r = − 0.15) (Supplementary Table 6).
Comparing the highest versus lowest tertiles, ER expression in normal TDLUs was non-
significantly but inversely associated with subsequent risk (odds ratio (OR) = 0.44, 95% 
confidence interval (CI) = 0.17–1.14, P trend = 0.68), whereas Ki67 expression was non-
significantly but positively associated with subsequent breast cancer risk (OR = 1.59, 95% 
CI = 0.80–3.14, P trend = 0.48; Table 1). PR expression was marginally associated with 
higher breast cancer risk (OR = 2.18, 95% CI = 1.04–4.57, P trend = 0.09); the association 
was statistically significant when restricted to premenopausal women (OR = 3.60, 95% CI = 
1.26–10.3, P trend = 0.04). Results were similar after adjustment for BBD subtype. After 
stratifying by BBD subtype, Ki67 was significantly associated with higher risk among 
women with atypical hyperplasia (OR = 6.80, 95% CI = 1.57–29.5, P interaction = 0.002; 
Table 2). Results were similar after conducting sensitivity analyses, which included 
excluding potential outliers, evaluating marker intensity scores, and using alternative 
cellularity cutpoints for exclusion criteria.
Our finding is consistent with a previous study of women with atypical hyperplasia that 
reported a fourfold higher breast cancer risk associated with Ki67 expression (≥2 vs. <2%)4 
and experimental studies that suggested carcinogenic potentials of PR.8 However, we did not 
observe a positive association with ER despite the supporting evidence.9,10 This study has 
limitations including potential measurement error in markers (for example, lack of data on 
menstrual phase, moderate correlations between automated and manual scores), which 
would bias results towards the null.
These findings contribute to our understanding of breast cancer biology and provide the 
basis for future studies investigating these markers as potential targets for risk assessment 
among women undergoing biopsies. However, given the small sample size and potential 
measurement error in markers, further studies are required to confirm these results.
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Table 1
Odds ratios and 95% confidence intervals of developing subsequent breast cancer according to tertiles of ER, 
PR, and Ki67 expression in normal breast tissue in the Nurses’ Health Study and the Nurses’ Health Study II
Case Control Model 1a OR (95% CI) Model 2b OR (95% CI)
Percentage of ER-positive cells (N = 175)
 <6.9% 17 41 1.0 (Ref) 1.0 (Ref)
 6.9–14.6% 15 44 0.69 (0.29, 1.66) 0.71 (0.29, 1.70)
 ≥14.7% 10 48 0.44 (0.17, 1.14) 0.45 (0.17, 1.17)
 Per 1% increase 0.99 (0.96, 1.03) 0.99 (0.96, 1.03)
 P trend 0.68 0.67
Percentage of PR-positive cells (N = 238)
 <4.0% 16 64 1.0 (Ref) 1.0 (Ref)
 4.0–9.8% 17 61 1.28 (0.58, 2.82) 1.27 (0.57, 2.82)
 ≥9.9% 26 54 2.18 (1.04, 4.57) 1.94 (0.91, 4.16)
 Per 1% increase 1.03 (1.00, 1.07) 1.03 (0.99, 1.07)
 P trend 0.09 0.18
Percentage of Ki67-positive cells (N = 285)
 <2.4% 20 75 1.0 (Ref) 1.0 (Ref)
 2.4–6.1% 18 77 0.92 (0.44, 1.93) 0.98 (0.46, 2.08)
 ≥6.2% 28 67 1.59 (0.80, 3.14) 1.79 (0.88, 3.62)
 Per 1% increase 1.01 (0.98, 1.05) 1.02 (0.98, 1.06)
 P trend 0.48 0.29
Abbreviations: CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor.
a
Model 1 (adjusted for matching factors only): age at diagnosis (continuous, years), calendar year of benign biopsy (<1970, 1970–1980, >1980), 
time since benign biopsy (continuous, years).
b
Model 2: Model 1+type of benign lesion (non-proliferative, proliferative without atypia, proliferative with atypical hyperplasia).
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Table 2
Odds ratios and 95% confidence intervals of developing subsequent breast cancer for ER, PR, Ki67 
expressiona in normal breast tissue stratified by benign lesion type in the Nurses’ Health Study and the Nurses’ 
Health Study II
Non-proliferative lesions Proliferative lesions without atypia Proliferative lesions with atypical hyperplasia
ER (≥10% vs. <10%)
 Case/control 8/35 18/63 16/35
 OR (95% CI)b 0.93 (0.18, 4.78) 0.64 (0.21, 1.94) 0.42 (0.10, 1.86)
 P trend 0.84 0.42 0.45
P interactionc =0.69
PR (≥6.5% vs. <6.5%)
 Case/control 10/54 26/90 23/35
 OR (95% CI)b 1.94 (0.48, 7.87) 1.94 (0.79, 4.74) 2.14 (0.60, 7.73)
 P trend 0.97 0.16 0.37
P interactionc =0.11
Ki67 (≥4.2% vs. <4.2%)
 Case/control 10/58 38/132 18/29
 OR (95% CI)b 4.29 (0.66, 27.8) 0.62 (0.29, 1.33) 6.80 (1.57, 29.5)
 P trend 0.05 0.62 0.03
P interactionc =0.002
Abbreviations: CI, confidence interval; ER, estrogen receptor; OR, odds ratio; PR, progesterone receptor.
a
ER, PR, and Ki67 expression in normal breast tissue was dichotomized around the median (above versus below median percentage of stain-
positive cells).
bAdjusted for matching factors only: age at diagnosis (continuous, years), calendar year of benign biopsy (<1970, >1970), time since benign biopsy 
(continuous, years).
cP interaction was estimated using the likelihood ratio test comparing models with and without the interaction terms between marker expression 
(high versus low) and BBD lesion type (proliferative lesions with atypical hyperplasia, proliferative lesions without atypia, and non-proliferative 
lesions).
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